High-Cost Cancer Drugs Could Become Up to 70% Cheaper
What Happened
The government is considering capping trade margins on cancer medicines at 30%, including some high-cost and patented drugs. The proposal is aimed at reducing excessive markups in the supply chain and could lower the maximum retail price (MRP) of certain cancer treatments by as much as 70%, according to reports. The move is part of a broader effort to improve affordability and access to oncology medicines.
Key Takeaways
If implemented, the margin cap could significantly reduce out-of-pocket expenses for cancer patients and make expensive therapies more accessible, though the final list of drugs and implementation details are yet to be announced.